JDRF Urges Senate to Support Insulin Affordability Provisions as Part of Inflation Reduction Act of 2022


JDRF believes that everyone, regardless of insurance status, should have access to affordable insulin. Nobody should suffer or die because they cannot afford insulin. To address this crisis, JDRF has long supported public and private sector actions to lower the out-of-pocket cost of insulin for people with diabetes. JDRF supports a project by non-profit pharmaceutical company Civica to manufacture and distribute low-cost biosimilar insulins available to all regardless of insurance status, and continues to work tirelessly to advance legislative provisions in Congress to reduce out-of-pocket costs and fix the broken insulin market.

Soon, the U.S. Senate will vote on the Inflation Reduction Act, which caps the cost of insulin at $35 per month and removes insulin from the deductible for people with Medicare or commercial insurance, places a $2,000 overall annual cap on prescription drug costs in Medicare, and continues tax credits that enable people to obtain health coverage at a low cost via the Affordable Care Act’s insurance marketplace. JDRF urges the Senate to support these provisions, which are big steps forward for the diabetes community on insulin affordability.

In addition to these provisions, JDRF calls on Congress to take up and pass as soon as possible the INSULIN Act to create an insulin certification pathway that corrects our broken system which incentivizes ever-increasing insulin list prices.

JDRF will continue working with the Biden Administration, Congress, and other stakeholders to promote comprehensive, long-term solutions that ensure everyone – whether they have insurance or not – can access insulin at a low and predictable cost.